

W Marston Linehan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1429121/publications.pdf>

Version: 2024-02-01

323
papers

40,210
citations

2543

96
h-index

2680

193
g-index

332
all docs

332
docs citations

332
times ranked

28199
citing authors

#	ARTICLE	IF	CITATIONS
1	Using Prostate Imaging-Reporting and Data System (PI-RADS) Scores to Select an Optimal Prostate Biopsy Method: A Secondary Analysis of the Trio Study. <i>European Urology Oncology</i> , 2022, 5, 176-186.	2.6	24
2	Seventh BHD international symposium: recent scientific and clinical advancement. <i>Oncotarget</i> , 2022, 13, 173-181.	0.8	4
3	MPAPASS software enables stitched multiplex, multidimensional EV repertoire analysis and a standard framework for reporting bead-based assays. <i>Cell Reports Methods</i> , 2022, 2, 100136.	1.4	8
4	Targeting chemoresistance in Xp11.2 translocation renal cell carcinoma using a novel polyamide-chlorambucil conjugate. <i>Cancer Science</i> , 2022, 113, 2352-2367.	1.7	3
5	Differential VHL Mutation Patterns in Bilateral Clear Cell RCC Distinguishes Between Independent Primary Tumors and Contralateral Metastatic Disease. <i>Urology</i> , 2022, 165, 170-177.	0.5	2
6	Single-cell transcriptomes underscore genetically distinct tumor characteristics and microenvironment for hereditary kidney cancers. <i>IScience</i> , 2022, 25, 104463.	1.9	4
7	A Histone Deacetylase Inhibitor Induces Acetyl-CoA Depletion Leading to Lethal Metabolic Stress in RAS-Pathway Activated Cells. <i>Cancers</i> , 2022, 14, 2643.	1.7	2
8	Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell Carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	4
9	Atherosclerotic Plaque Burden on Abdominal CT: Automated Assessment With Deep Learning on Noncontrast and Contrast-enhanced Scans. <i>Academic Radiology</i> , 2021, 28, 1491-1499.	1.3	22
10	Clinical and Molecular Characterization of Microphthalmia-associated Transcription Factor (MITF)-related Renal Cell Carcinoma. <i>Urology</i> , 2021, 149, 89-97.	0.5	22
11	Long term outcomes for patients with von Hippel-Lindau and Pheochromocytoma: defining the role of active surveillance. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 134.e1-134.e8.	0.8	11
12	MicroRNA Profiling of Morphologically Heterogeneous Clear Cell Renal Cell Carcinoma. <i>Journal of Cancer</i> , 2021, 12, 5375-5384.	1.2	2
13	Glycolytic metabolism of pathogenic T cells enables early detection of GVHD by 13C-MRI. <i>Blood</i> , 2021, 137, 126-137.	0.6	29
14	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. <i>Nature Communications</i> , 2021, 12, 808.	5.8	84
15	Precision Surgery and Kidney Cancer: Knowledge of Genetic Alterations Influences Surgical Management. <i>Genes</i> , 2021, 12, 261.	1.0	12
16	¹⁸ F-fluorodeoxyglucose-positron emission tomography/computed tomography for differentiation of renal tumors in hereditary kidney cancer syndromes. <i>Abdominal Radiology</i> , 2021, 46, 3301-3308.	1.0	4
17	Comprehensive characterization of Alu-mediated breakpoints in germline VHL gene deletions and rearrangements in patients from 71 VHL families. <i>Human Mutation</i> , 2021, 42, 520-529.	1.1	6
18	Characterization of genetically defined sporadic and hereditary type 1 papillary renal cell carcinoma cell lines. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 434-446.	1.5	10

#	ARTICLE	IF	CITATIONS
19	Therapeutic inhibition of HIF-2 α reverses polycythemia and pulmonary hypertension in murine models of human diseases. <i>Blood</i> , 2021, 137, 2509-2519.	0.6	24
20	Fe-S cofactors in the SARS-CoV-2 RNA-dependent RNA polymerase are potential antiviral targets. <i>Science</i> , 2021, 373, 236-241.	6.0	71
21	A deep-learning based artificial intelligence (AI) approach for differentiation of clear cell renal cell carcinoma from oncocytoma on multi-phasic MRI. <i>Clinical Imaging</i> , 2021, 77, 291-298.	0.8	25
22	Macronodular adrenal hyperplasia masquerading as an upper pole renal mass. <i>Urology Case Reports</i> , 2021, 37, 101603.	0.1	0
23	Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement. <i>Cancer</i> , 2021, 127, 3957-3966.	2.0	11
24	X-Capsular Incision for Tumor Enucleation (X-CITE)-Technique: A Method to Maximize Renal Parenchymal Preservation for Completely Endophytic Renal Tumors. <i>Urology</i> , 2021, 154, 315-319.	0.5	6
25	The tumor suppressor folliculin inhibits lactate dehydrogenase A and regulates the Warburg effect. <i>Nature Structural and Molecular Biology</i> , 2021, 28, 662-670.	3.6	19
26	Reoperative Partial Nephrectomyâ€”Does Previous Surgical Footprint Impact Outcomes?. <i>Journal of Urology</i> , 2021, 206, 539-547.	0.2	10
27	Intravitreal treatment of severe ocular von Hippel-Lindau disease using a combination of the VEGF inhibitor, ranibizumab and PDGF inhibitor, E10030: Results from a phase 1/2 clinical trial. <i>Clinical and Experimental Ophthalmology</i> , 2021, 49, 1048-1059.	1.3	5
28	Mitochondrial DNA alterations underlie an irreversible shift to aerobic glycolysis in fumarate hydratase-deficient renal cancer. <i>Science Signaling</i> , 2021, 14, .	1.6	64
29	Tobacco smoking induces metabolic reprogramming of renal cell carcinoma. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	14
30	FLCN alteration drives metabolic reprogramming towards nucleotide synthesis and cyst formation in salivary gland. <i>Biochemical and Biophysical Research Communications</i> , 2020, 522, 931-938.	1.0	5
31	Heterogeneous adaptation of cysteine reactivity to a covalent oncometabolite. <i>Journal of Biological Chemistry</i> , 2020, 295, 13410-13418.	1.6	7
32	A germline 1;3 translocation disrupting the VHL gene: a novel genetic cause for von Hippel-Lindau. <i>Journal of Medical Genetics</i> , 2020, , jmedgenet-2020-107308.	1.5	8
33	Fumarate hydratase-deficient renal cell carcinoma cells respond to asparagine by activation of the unfolded protein response and stimulation of the hexosamine biosynthetic pathway. <i>Cancer & Metabolism</i> , 2020, 8, 7.	2.4	2
34	Blood and lymphatic systems are segregated by the FLCN tumor suppressor. <i>Nature Communications</i> , 2020, 11, 6314.	5.8	17
35	Salvage robotic transmesenteric off-clamp partial nephrectomy after multiple prior open kidney surgeries. <i>Urology Case Reports</i> , 2020, 30, 101135.	0.1	0
36	Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome: Spectrum of imaging findings. <i>Clinical Imaging</i> , 2020, 68, 14-19.	0.8	10

#	ARTICLE	IF	CITATIONS
37	Growth Rates of Genetically Defined Renal Tumors: Implications for Active Surveillance and Intervention. <i>Journal of Clinical Oncology</i> , 2020, 38, 1146-1153.	0.8	39
38	Long-term Functional and Oncologic Outcomes of Partial Adrenalectomy for Pheochromocytoma. <i>Urology</i> , 2020, 140, 85-90.	0.5	15
39	An Oncometabolite Isomer Rapidly Induces a Pathophysiological Protein Modification. <i>ACS Chemical Biology</i> , 2020, 15, 856-861.	1.6	4
40	Determination of the Expression of PD-L1 in the Morphologic Spectrum of Renal Cell Carcinoma. <i>Journal of Cancer</i> , 2020, 11, 3596-3603.	1.2	17
41	Novel renal medullary carcinoma cell lines, <sc>UOK353</sc> and <sc>UOK360</sc>, provide preclinical tools to identify new therapeutic treatments. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 472-483.	1.5	7
42	Clear Cell Renal Cell Carcinoma Growth Correlates with Baseline Diffusion-weighted MRI in Von Hippel-Lindau Disease. <i>Radiology</i> , 2020, 295, 583-590.	3.6	10
43	Dynamic Imaging of LDH Inhibition in Tumors Reveals Rapid In Vivo Metabolic Rewiring and Vulnerability to Combination Therapy. <i>Cell Reports</i> , 2020, 30, 1798-1810.e4.	2.9	73
44	A FLCN-TFE3 Feedback Loop Prevents Excessive Glycogenesis and Phagocyte Activation by Regulating Lysosome Activity. <i>Cell Reports</i> , 2020, 30, 1823-1834.e5.	2.9	18
45	Phase II study of the oral HIF-2 α inhibitor MK-6482 for Von Hippel-Lindau disease-associated renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5003-5003.	0.8	40
46	Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5004-5004.	0.8	53
47	Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights. <i>European Urology</i> , 2019, 76, 754-764.	0.9	80
48	The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications. <i>Nature Reviews Urology</i> , 2019, 16, 539-552.	1.9	357
49	Obstructive azoospermia secondary to bilateral epididymal cystadenomas in a patient with von Hippel-Lindau. <i>Urology Case Reports</i> , 2019, 27, 100922.	0.1	5
50	Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. <i>Cell</i> , 2019, 179, 964-983.e31.	13.5	430
51	A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor. <i>Clinical Cancer Research</i> , 2019, 25, 6302-6308.	3.2	13
52	Post-translational Regulation of FNIP1 Creates a Rheostat for the Molecular Chaperone Hsp90. <i>Cell Reports</i> , 2019, 26, 1344-1356.e5.	2.9	38
53	MicroRNA-204-5p: A novel candidate urinary biomarker of Xp11.2 translocation renal cell carcinoma. <i>Cancer Science</i> , 2019, 110, 1897-1908.	1.7	55
54	TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease. <i>Molecular Cancer Research</i> , 2019, 17, 1613-1626.	1.5	35

#	ARTICLE	IF	CITATIONS
55	The Metabolic Basis of Kidney Cancer. <i>Cancer Discovery</i> , 2019, 9, 1006-1021.	7.7	163
56	Birt-Hogg-DubÃ© syndrome initially diagnosed as tuberous sclerosis complex. <i>JAAD Case Reports</i> , 2019, 5, 368-371.	0.4	9
57	Salvage Surgery After Percutaneous Ablation of Renal Mass in Solitary Kidney in a Patient With Von Hippel-Lindau. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e482-e484.	0.9	1
58	Metabolic Labeling of Cultured Mammalian Cells for Stable Isotope-Resolved Metabolomics: Practical Aspects of Tissue Culture and Sample Extraction. <i>Methods in Molecular Biology</i> , 2019, 1928, 1-27.	0.4	12
59	Proteasome inhibition disrupts the metabolism of fumarate hydratase-deficient tumors by downregulating p62 and c-Myc. <i>Scientific Reports</i> , 2019, 9, 18409.	1.6	10
60	Dual functions of angiopoietin-like protein 2 signaling in tumor progression and anti-tumor immunity. <i>Genes and Development</i> , 2019, 33, 1641-1656.	2.7	9
61	Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 1-6.	0.9	60
62	Differences in Tumor VHL Mutation and Hypoxia-inducible Factor 2 β Expression Between African American and White Patients with Clear Cell Renal Cell Carcinoma. <i>European Urology</i> , 2019, 75, 882-884.	0.9	3
63	Photoinducible Oncometabolite Detection. <i>ChemBioChem</i> , 2019, 20, 360-365.	1.3	16
64	Germline mutations of renal cancer predisposition genes and clinical relevance in Chinese patients with sporadic, early-onset disease. <i>Cancer</i> , 2019, 125, 1060-1069.	2.0	28
65	CDC73 Germline Mutation in a Family With Mixed Epithelial and Stromal Tumors. <i>Urology</i> , 2019, 124, 91-97.	0.5	20
66	Cumulative Radiation Exposures from CT Screening and Surveillance Strategies for von Hippel-Lindau-associated Solid Pancreatic Tumors. <i>Radiology</i> , 2019, 290, 116-124.	3.6	7
67	A chemoproteomic portrait of the oncometabolite fumarate. <i>Nature Chemical Biology</i> , 2019, 15, 391-400.	3.9	77
68	Imaging of glucose metabolism by ¹³ C-MRI distinguishes pancreatic cancer subtypes in mice. <i>ELife</i> , 2019, 8, .	2.8	19
69	Multi-regional Sequencing Elucidates the Evolution of Clear Cell Renal Cell Carcinoma. <i>Cell</i> , 2018, 173, 540-542.	13.5	37
70	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. <i>Cell Reports</i> , 2018, 23, 313-326.e5.	2.9	523
71	In silico VHL Gene Mutation Analysis and Prognosis of Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1631-1638.	1.8	12
72	Acute loss of iron-sulfur clusters results in metabolic reprogramming and generation of lipid droplets in mammalian cells. <i>Journal of Biological Chemistry</i> , 2018, 293, 8297-8311.	1.6	70

#	ARTICLE	IF	CITATIONS
73	Mithramycin A Enhances Tumor Sensitivity to Mitotic Catastrophe Resulting From DNA Damage. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 344-352.	0.4	7
74	Association of <i>VHL</i> Genotype With Pancreatic Neuroendocrine Tumor Phenotype in Patients With von Hippel-Lindau Disease. <i>JAMA Oncology</i> , 2018, 4, 124.	3.4	44
75	FLCN : The causative gene for Birt-Hogg-Dubé syndrome. <i>Gene</i> , 2018, 640, 28-42.	1.0	133
76	Superiority of ⁶⁸ Ga-DOTATATE over ¹⁸ F-FDG and anatomic imaging in the detection of succinate dehydrogenase mutation (SDHx)-related pheochromocytoma and paraganglioma in the pediatric population. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 787-797.	3.3	64
77	Metabolic Pathways in Kidney Cancer: Current Therapies and Future Directions. <i>Journal of Clinical Oncology</i> , 2018, 36, 3540-3546.	0.8	41
78	ONC201 kills breast cancer cells <i>in vitro</i> by targeting mitochondria. <i>Oncotarget</i> , 2018, 9, 18454-18479.	0.8	77
79	Pathologic Oxidation of PTPN12 Underlies ABL1 Phosphorylation in Hereditary Leiomyomatosis and Renal Cell Carcinoma. <i>Cancer Research</i> , 2018, 78, 6539-6548.	0.4	12
80	The Warburg effect in hominis: isotope-resolved metabolism in ccRCC. <i>Nature Reviews Urology</i> , 2018, 15, 731-732.	1.9	4
81	Targeting loss of the Hippo signaling pathway in <i>NF2</i> -deficient papillary kidney cancers. <i>Oncotarget</i> , 2018, 9, 10723-10733.	0.8	35
82	BHD-associated kidney cancer exhibits unique molecular characteristics and a wide variety of variants in chromatin remodeling genes. <i>Human Molecular Genetics</i> , 2018, 27, 2712-2724.	1.4	14
83	Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 5977-5989.	3.2	58
84	Evaluation of Recipients of Positive and Negative Secondary Findings Evaluations in a Hybrid CLIA-Research Sequencing Pilot. <i>American Journal of Human Genetics</i> , 2018, 103, 358-366.	2.6	29
85	The origin, evolution and route to metastasis of clear cell RCC. <i>Nature Reviews Nephrology</i> , 2018, 14, 538-540.	4.1	6
86	Discovering Targets of Non-enzymatic Acylation by Thioester Reactivity Profiling. <i>Cell Chemical Biology</i> , 2017, 24, 231-242.	2.5	79
87	Comprehensive genomic and phenotypic characterization of germline <i>FH</i> deletion in hereditary leiomyomatosis and renal cell carcinoma. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 484-492.	1.5	21
88	Managing Renal Cell Carcinoma Associated Paraneoplastic Syndrome with Nephron-sparing Surgery in a Patient with von Hippel-Lindau. <i>Urology Case Reports</i> , 2017, 13, 101-103.	0.1	1
89	RCC " advances in targeted therapeutics and genomics. <i>Nature Reviews Urology</i> , 2017, 14, 76-78.	1.9	14
90	Insights into Epigenetic Remodeling in VHL-Deficient Clear Cell Renal Cell Carcinoma. <i>Cancer Discovery</i> , 2017, 7, 1221-1223.	7.7	8

#	ARTICLE	IF	CITATIONS
91	Recommendations for the Management of Rare Kidney Cancers. <i>European Urology</i> , 2017, 72, 974-983.	0.9	36
92	Genomic and metabolic characterization of a chromophobe renal cell carcinoma cell line model (UOK276). <i>Genes Chromosomes and Cancer</i> , 2017, 56, 719-729.	1.5	14
93	Multiple Recurrent Paraganglioma in a Pediatric Patient with Germline SDH-B Mutation. <i>Urology Case Reports</i> , 2017, 13, 107-109.	0.1	1
94	A mouse model of renal cell carcinoma. <i>Nature Medicine</i> , 2017, 23, 802-803.	15.2	3
95	Persistent Severe Hyperlactatemia and Metabolic Derangement in Lethal <i>SDHB</i> -Mutated Metastatic Kidney Cancer: Clinical Challenges and Examples of Extreme Warburg Effect. <i>JCO Precision Oncology</i> , 2017, 1, 1-14.	1.5	9
96	Hereditary Renal Cell Carcinoma. , 2017, , 19-82.		1
97	Haploinsufficiency in tumor predisposition syndromes: altered genomic transcription in morphologically normal cells heterozygous for <i>VHL</i> or <i>TSC</i> mutation. <i>Oncotarget</i> , 2017, 8, 17628-17642.	0.8	11
98	Loss of <i>Folliculin</i> Disrupts Hematopoietic Stem Cell Quiescence and Homeostasis Resulting in Bone Marrow Failure. <i>Stem Cells</i> , 2016, 34, 1068-1082.	1.4	25
99	Patient-specific factors influence somatic variation patterns in von Hippel-Lindau disease renal tumours. <i>Nature Communications</i> , 2016, 7, 11588.	5.8	24
100	H255Y and K508R missense mutations in tumour suppressor folliculin (<i>FLCN</i>) promote kidney cell proliferation. <i>Human Molecular Genetics</i> , 2016, 26, ddw392.	1.4	17
101	SnapShot: Renal Cell Carcinoma. <i>Cancer Cell</i> , 2016, 29, 610-610.e1.	7.7	35
102	Hypoxia-Inducible Factor 2 ^{1±} Mutation-Related Paragangliomas Classify as Discrete Pseudohypoxic Subcluster. <i>Neoplasia</i> , 2016, 18, 567-576.	2.3	16
103	Genetic predisposition to kidney cancer. <i>Seminars in Oncology</i> , 2016, 43, 566-574.	0.8	107
104	Targeting HIF2 ^{1±} in Clear-Cell Renal Cell Carcinoma. <i>Cancer Cell</i> , 2016, 30, 515-517.	7.7	23
105	Repeat Robotic Partial Nephrectomy: Characteristics, Complications, and Renal Functional Outcomes. <i>Journal of Endourology</i> , 2016, 30, 1219-1226.	1.1	25
106	Renal functional outcomes after robotic multiplex partial nephrectomy: the National Cancer Institute experience with robotic partial nephrectomy for 3 or more tumors in a single kidney. <i>International Urology and Nephrology</i> , 2016, 48, 1817-1821.	0.6	18
107	Co-opting a Bioorthogonal Reaction for Oncometabolite Detection. <i>Journal of the American Chemical Society</i> , 2016, 138, 15813-15816.	6.6	25
108	The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding. <i>Nature Communications</i> , 2016, 7, 12037.	5.8	56

#	ARTICLE	IF	CITATIONS
109	Postoperative elevation in creatine kinase and its impact on renal function in patients undergoing complex partial nephrectomy. <i>International Urology and Nephrology</i> , 2016, 48, 1047-1053.	0.6	7
110	Biodistribution and Efficacy of Low Temperature-Sensitive Liposome Encapsulated Docetaxel Combined with Mild Hyperthermia in a Mouse Model of Prostate Cancer. <i>Pharmaceutical Research</i> , 2016, 33, 2459-2469.	1.7	8
111	Vascular Endothelial Growth Factor Receptor-Targeted Therapy in Succinate Dehydrogenase C Kidney Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, e76-e79.	0.8	7
112	Detection of an Immunogenic HERV-E Envelope with Selective Expression in Clear Cell Kidney Cancer. <i>Cancer Research</i> , 2016, 76, 2177-2185.	0.4	86
113	PET/CT imaging of renal cell carcinoma with 18F-VM4-037: a phase II pilot study. <i>Abdominal Radiology</i> , 2016, 41, 109-118.	1.0	35
114	Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2016, 374, 135-145.	13.9	1,040
115	Biological and clinical impact of hemangioblastoma-associated peritumoral cysts in von Hippel-Lindau disease. <i>Journal of Neurosurgery</i> , 2016, 124, 971-976.	0.9	37
116	SDHB-Deficient Cancers: The Role of Mutations That Impair Iron Sulfur Cluster Delivery. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv287.	3.0	92
117	Alternative splicing of the cell fate determinant Numb in hepatocellular carcinoma. <i>Hepatology</i> , 2015, 62, 1122-1131.	3.6	91
118	Metabolism and Oxidative Stress Response Pathways in Kidney Cancer: A Tale of Chance and Necessity. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , 220-225.	1.8	4
119	Comedonal and Cystic Fibrofolliculomas in Birt-Hogg-Dube Syndrome. <i>JAMA Dermatology</i> , 2015, 151, 770.	2.0	28
120	Clinical features, genetics and potential therapeutic approaches for Birt-Hogg-Dub syndrome. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 15-29.	0.5	43
121	New Strategies in Renal Cell Carcinoma: Targeting the Genetic and Metabolic Basis of Disease. <i>Clinical Cancer Research</i> , 2015, 21, 10-17.	3.2	88
122	The Metabolic Basis of Kidney Cancer. , 2015, , 89-102.		1
123	Comparison of MR/Ultrasound Fusion-Guided Biopsy With Ultrasound-Guided Biopsy for the Diagnosis of Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 390.	3.8	1,267
124	Association of urinary bladder paragangliomas with germline mutations in the SDHB and VHL genes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 167.e13-167.e20.	0.8	24
125	Folliculin-interacting proteins Fnip1 and Fnip2 play critical roles in kidney tumor suppression in cooperation with Flcn. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E1624-31.	3.3	74
126	Mitochondrial DNA mutations distinguish bilateral multifocal renal oncocytomas from familial Birt-Hogg-Dub tumors. <i>Modern Pathology</i> , 2015, 28, 1458-1469.	2.9	23

#	ARTICLE	IF	CITATIONS
127	Efficacy of Intralesional Botulinum Toxin A for Treatment of Painful Cutaneous Leiomyomas. <i>JAMA Dermatology</i> , 2015, 151, 1096.	2.0	15
128	Molecular genetics and clinical features of Birtâ€“Hoggâ€“DubÃ© syndrome. <i>Nature Reviews Urology</i> , 2015, 12, 558-569.	1.9	175
129	Gender Specific Mutation Incidence and Survival Associations in Clear Cell Renal Cell Carcinoma (CCRCC). <i>PLoS ONE</i> , 2015, 10, e0140257.	1.1	56
130	Tonantzitlolone cytotoxicity toward renal cancer cells is PKCÎ¿- and HSF1-dependent. <i>Oncotarget</i> , 2015, 6, 29963-29974.	0.8	15
131	Hereditary leiomyomatosis and renal cell carcinoma. <i>International Journal of Nephrology and Renovascular Disease</i> , 2014, 7, 253.	0.8	112
132	Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment. <i>Familial Cancer</i> , 2014, 13, 637-644.	0.9	251
133	Looking forward, looking backâ€”10 years in urology. <i>Nature Reviews Urology</i> , 2014, 11, 649-655.	1.9	4
134	Targeting ABL1-Mediated Oxidative Stress Adaptation in Fumarate Hydratase-Deficient Cancer. <i>Cancer Cell</i> , 2014, 26, 840-850.	7.7	87
135	Pathologic validation of renal cell carcinoma histology in the Surveillance, Epidemiology, and End Results program. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 23.e9-23.e13.	0.8	30
136	Folliculin Controls Lung Alveolar Enlargement and Epithelial Cell Survival through E-Cadherin, LKB1, and AMPK. <i>Cell Reports</i> , 2014, 7, 412-423.	2.9	84
137	The Genetic Basis of Pheochromocytoma and Paraganglioma: Implications for Management. <i>Urology</i> , 2014, 83, 1225-1232.	0.5	40
138	Intratumoral heterogeneity in kidney cancer. <i>Nature Genetics</i> , 2014, 46, 214-215.	9.4	44
139	Folliculin (Flcn) inactivation leads to murine cardiac hypertrophy through mTORC1 deregulation. <i>Human Molecular Genetics</i> , 2014, 23, 5706-5719.	1.4	54
140	The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma. <i>Cancer Cell</i> , 2014, 26, 319-330.	7.7	665
141	Prospective Evaluation of the Clinical Utility of 18-Fluorodeoxyglucose PET CT Scanning in Patients with Von Hippel-Lindauâ€“Associated Pancreatic Lesions. <i>Journal of the American College of Surgeons</i> , 2014, 218, 997-1003.	0.2	14
142	Discoveries, therapies and opportunities. <i>Nature Reviews Urology</i> , 2014, 11, 614-616.	1.9	24
143	Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers. <i>Nature Reviews Urology</i> , 2014, 11, 465-475.	1.9	227
144	Defining Early-Onset Kidney Cancer: Implications for Germline and Somatic Mutation Testing and Clinical Management. <i>Journal of Clinical Oncology</i> , 2014, 32, 431-437.	0.8	135

#	ARTICLE	IF	CITATIONS
145	Editorial Comment. <i>Urology</i> , 2014, 83, 675.e5.	0.5	1
146	Use of nephron-sparing surgery among renal cell carcinoma patients with diabetes and hypertension. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 27.e15-27.e21.	0.8	8
147	Oxidation of Alpha-Ketoglutarate Is Required for Reductive Carboxylation in Cancer Cells with Mitochondrial Defects. <i>Cell Reports</i> , 2014, 7, 1679-1690.	2.9	281
148	Tumor-Specific Hypermethylation of Epigenetic Biomarkers, Including SFRP1, Predicts for Poorer Survival in Patients from the TCGA Kidney Renal Clear Cell Carcinoma (KIRC) Project. <i>PLoS ONE</i> , 2014, 9, e85621.	1.1	58
149	Englerin A Stimulates PKC δ to Inhibit Insulin Signaling and to Simultaneously Activate HSF1: Pharmacologically Induced Synthetic Lethality. <i>Cancer Cell</i> , 2013, 23, 228-237.	7.7	74
150	A Novel Germline Mutation in <i>BAP1</i> Predisposes to Familial Clear-Cell Renal Cell Carcinoma. <i>Molecular Cancer Research</i> , 2013, 11, 1061-1071.	1.5	135
151	Non-Clear Cell Renal Cancer: Disease-Based Management and Opportunities for Targeted Therapeutic Approaches. <i>Seminars in Oncology</i> , 2013, 40, 511-520.	0.8	36
152	Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 181-186.	0.8	401
153	Metabolism of Kidney Cancer: From the Lab to Clinical Practice. <i>European Urology</i> , 2013, 63, 244-251.	0.9	61
154	Germline PTEN Mutation Cowden Syndrome: An Underappreciated Form of Hereditary Kidney Cancer. <i>Journal of Urology</i> , 2013, 190, 1990-1998.	0.2	85
155	The metabolic basis of kidney cancer. <i>Seminars in Cancer Biology</i> , 2013, 23, 46-55.	4.3	132
156	Treating advanced kidney cancer—miles to go before we sleep. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 614-615.	12.5	4
157	Diagnosis and management of BHD-associated kidney cancer. <i>Familial Cancer</i> , 2013, 12, 397-402.	0.9	85
158	Impact of Ischemia and Procurement Conditions on Gene Expression in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2013, 19, 42-49.	3.2	36
159	Molecular Pathways: <i>Fumarate Hydratase</i> -Deficient Kidney Cancer—Targeting the Warburg Effect in Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 3345-3352.	3.2	172
160	Phase II trial of vandetanib in Von Hippel-Lindau-associated renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 4584-4584.	0.8	3
161	Defining early-onset kidney cancer: Implications for genetic counseling. <i>Journal of Clinical Oncology</i> , 2013, 31, 342-342.	0.8	2
162	Clinical evaluation of 2-(18F) fluoro-2 deoxy-D-glucose PET/ CT in hereditary leiomyomatosis and renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 383-383.	0.8	3

#	ARTICLE	IF	CITATIONS
163	Metabolic Reprogramming for Producing Energy and Reducing Power in Fumarate Hydratase Null Cells from Hereditary Leiomyomatosis Renal Cell Carcinoma. PLoS ONE, 2013, 8, e72179.	1.1	80
164	Paragangliomas of the urinary bladder: Experience at the National Cancer Institute.. Journal of Clinical Oncology, 2013, 31, 307-307.	0.8	1
165	Regulation of Mitochondrial Oxidative Metabolism by Tumor Suppressor FLCN. Journal of the National Cancer Institute, 2012, 104, 1750-1764.	3.0	82
166	Genetic basis of kidney cancer: Role of genomics for the development of disease-based therapeutics. Genome Research, 2012, 22, 2089-2100.	2.4	202
167	Sarcomatoid Renal Cell Carcinoma: A Comprehensive Review of the Biology and Current Treatment Strategies. Oncologist, 2012, 17, 46-54.	1.9	177
168	Translocation Renal Cell Carcinomas in Adults. American Journal of Surgical Pathology, 2012, 36, 654-662.	2.1	98
169	The folliculin-FNIP1 pathway deleted in human Birt-Hogg-Dubé syndrome is required for murine B-cell development. Blood, 2012, 120, 1254-1261.	0.6	57
170	Kidney cancer. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 948-951.	0.8	31
171	Succinate Dehydrogenase Kidney Cancer: An Aggressive Example of the Warburg Effect in Cancer. Journal of Urology, 2012, 188, 2063-2071.	0.2	211
172	A novel fumarate hydratase-deficient HLRCC kidney cancer cell line, UOK268: a model of the Warburg effect in cancer. Cancer Genetics, 2012, 205, 377-390.	0.2	55
173	Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature, 2012, 481, 385-388.	13.7	1,074
174	Correlation of Magnetic Resonance Imaging Tumor Volume with Histopathology. Journal of Urology, 2012, 188, 1157-1163.	0.2	188
175	Multiparametric Magnetic Resonance Imaging and Ultrasound Fusion Biopsy Detect Prostate Cancer in Patients with Prior Negative Transrectal Ultrasound Biopsies. Journal of Urology, 2012, 188, 2152-2157.	0.2	227
176	Inhibition of Hypoxia Inducible Factor-2 Transcription: Isolation of Active Modulators from Marine Sponges. Journal of Natural Products, 2012, 75, 1632-1636.	1.5	15
177	The Genetic Basis of Kidney Cancer: Implications for Management and Use of Targeted Therapeutic Approaches. European Urology, 2012, 61, 896-898.	0.9	23
178	Treatment of Advanced Renal Cell Carcinoma. , 2012, , 1475-1491.e5.		4
179	Targeting HIF2 α Translation with Tempol in VHL-Deficient Clear Cell Renal Cell Carcinoma. Oncotarget, 2012, 3, 1472-1482.	0.8	20
180	Metabolic evaluation of sporadic papillary kidney cancer.. Journal of Clinical Oncology, 2012, 30, 377-377.	0.8	0

#	ARTICLE	IF	CITATIONS
181	Measurements of Plasma Methoxytyramine, Normetanephrine, and Metanephrine as Discriminators of Different Hereditary Forms of Pheochromocytoma. <i>Clinical Chemistry</i> , 2011, 57, 411-420.	1.5	282
182	Von Hippel-Lindau (VHL) Inactivation in Sporadic Clear Cell Renal Cancer: Associations with Germline VHL Polymorphisms and Etiologic Risk Factors. <i>PLoS Genetics</i> , 2011, 7, e1002312.	1.5	168
183	Robot-assisted Laparoscopic Partial Adrenalectomy: Initial Experience. <i>Urology</i> , 2011, 77, 775-780.	0.5	47
184	Regulatory Effects of microRNA-92 (miR-92) on <i>VHL</i> Gene Expression and the Hypoxic Activation of miR-210 in Clear Cell Renal Cell Carcinoma. <i>Journal of Cancer</i> , 2011, 2, 515-526.	1.2	69
185	Differential Genetic Expression in Large Versus Small Clear Cell Renal Cell Carcinoma: Results from Microarray Analysis. <i>Journal of Cancer</i> , 2011, 2, 271-279.	1.2	4
186	Familial Renal Cancer: Molecular Genetics and Surgical Management. <i>International Journal of Surgical Oncology</i> , 2011, 2011, 1-11.	0.3	21
187	Robot-Assisted Laparoscopic Partial Adrenalectomy for Pheochromocytoma: The National Cancer Institute Technique. <i>European Urology</i> , 2011, 60, 118-124.	0.9	58
188	The Glycolytic Shift in Fumarate-Hydratase-Deficient Kidney Cancer Lowers AMPK Levels, Increases Anabolic Propensities and Lowers Cellular Iron Levels. <i>Cancer Cell</i> , 2011, 20, 315-327.	7.7	190
189	Impact of Genetics on the Diagnosis and Treatment of Renal Cancer. <i>Current Urology Reports</i> , 2011, 12, 47-55.	1.0	20
190	Identification of intragenic deletions and duplication in the <i>FLCN</i> gene in Birt-Hogg-Dubé syndrome. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 466-477.	1.5	50
191	Identification and evaluation of soft coral diterpenes as inhibitors of HIF-2 α induced gene expression. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 2113-2115.	1.0	23
192	Dual-color, Break-apart FISH Assay on Paraffin-embedded Tissues as an Adjunct to Diagnosis of Xp11 Translocation Renal Cell Carcinoma and Alveolar Soft Part Sarcoma. <i>American Journal of Surgical Pathology</i> , 2010, 34, 757-766.	2.1	111
193	Targeted therapies for non-clear renal cell carcinoma. <i>Targeted Oncology</i> , 2010, 5, 119-129.	1.7	32
194	UOK 262 cell line, fumarate hydratase deficient (FH ^{-/-} /FH ^{-/-}) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. <i>Cancer Genetics and Cytogenetics</i> , 2010, 196, 45-55.	1.0	131
195	Catecholamine metabolomic and secretory phenotypes in pheochromocytoma. <i>Endocrine-Related Cancer</i> , 2010, 18, 97-111.	1.6	169
196	Increasing reactive oxygen species as a therapeutic approach to treat hereditary leiomyomatosis and renal cell carcinoma. <i>Cell Cycle</i> , 2010, 9, 4183-4189.	1.3	25
197	Molecular Diagnosis and Therapy of Kidney Cancer. <i>Annual Review of Medicine</i> , 2010, 61, 329-343.	5.0	154
198	Tumor suppressor FLCN inhibits tumorigenesis of a FLCN-null renal cancer cell line and regulates expression of key molecules in TGF- β signaling. <i>Molecular Cancer</i> , 2010, 9, 160.	7.9	81

#	ARTICLE	IF	CITATIONS
199	A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic Renal Cell Carcinoma. <i>Journal of Translational Medicine</i> , 2010, 8, 8.	1.8	29
200	Functional and Oncologic Outcomes of Partial Adrenalectomy for Pheochromocytoma in Patients With von Hippel-Lindau Syndrome After at Least 5 Years of Followup. <i>Journal of Urology</i> , 2010, 184, 1855-1859.	0.2	66
201	The genetic basis of kidney cancer: a metabolic disease. <i>Nature Reviews Urology</i> , 2010, 7, 277-285.	1.9	634
202	Inactivation of the FLCN Tumor Suppressor Gene Induces TFE3 Transcriptional Activity by Increasing Its Nuclear Localization. <i>PLoS ONE</i> , 2010, 5, e15793.	1.1	146
203	Fumarate Hydratase Deficiency in Renal Cancer Induces Glycolytic Addiction and Hypoxia-Inducible Transcription Factor 1 α Stabilization by Glucose-Dependent Generation of Reactive Oxygen Species. <i>Molecular and Cellular Biology</i> , 2009, 29, 4080-4090.	1.1	212
204	Genetic Basis of Bilateral Renal Cancer: Implications for Evaluation and Management. <i>Journal of Clinical Oncology</i> , 2009, 27, 3731-3733.	0.8	17
205	Homozygous loss of <i>BHD</i> causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 18722-18727.	3.3	203
206	Targeting the Met signaling pathway in renal cancer. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 785-793.	1.1	66
207	Innovations and challenges in renal cancer: Summary statement from the Third Cambridge Conference. <i>Cancer</i> , 2009, 115, 2247-2251.	2.0	24
208	Hereditary kidney cancer. <i>Cancer</i> , 2009, 115, 2252-2261.	2.0	101
209	VHL loss of function and its impact on oncogenic signaling networks in clear cell renal cell carcinoma. <i>International Journal of Biochemistry and Cell Biology</i> , 2009, 41, 753-756.	1.2	49
210	Initial Experience With Robot Assisted Partial Nephrectomy for Multiple Renal Masses. <i>Journal of Urology</i> , 2009, 182, 1280-1286.	0.2	66
211	The UOK 257 cell line: a novel model for studies of the human Birt-Hogg-Dub \otimes gene pathway. <i>Cancer Genetics and Cytogenetics</i> , 2008, 180, 100-109.	1.0	55
212	Robotic Partial Nephrectomy for Complex Renal Tumors: Surgical Technique. <i>European Urology</i> , 2008, 53, 514-523.	0.9	210
213	Kidney cancer: Opportunity for disease specific targeted therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2008, 26, 542.	0.8	4
214	Identification and characterization of a novel folliculin-interacting protein FNIP2. <i>Gene</i> , 2008, 415, 60-67.	1.0	163
215	Robotic Partial Nephrectomy for Renal Hilar Tumors: A Multi-Institutional Analysis. <i>Journal of Urology</i> , 2008, 180, 2353-2356.	0.2	147
216	Salvage Partial Nephrectomy for Hereditary Renal Cancer: Feasibility and Outcomes. <i>Journal of Urology</i> , 2008, 179, 67-70.	0.2	83

#	ARTICLE	IF	CITATIONS
217	Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors. <i>Clinical Cancer Research</i> , 2008, 14, 4726-4734.	3.2	503
218	Association of Germline Mutations in the Fumarate Hydratase Gene and Uterine Fibroids in Women With Hereditary Leiomyomatosis and Renal Cell Cancer. <i>Archives of Dermatology</i> , 2008, 144, 1584-92.	1.7	83
219	Kidney-Targeted Birt-Hogg-Dube Gene Inactivation in a Mouse Model: Erk1/2 and Akt-mTOR Activation, Cell Hyperproliferation, and Polycystic Kidneys. <i>Journal of the National Cancer Institute</i> , 2008, 100, 140-154.	3.0	223
220	Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 779-790.	1.4	51
221	Identification of the Genes for Kidney Cancer: Opportunity for Disease-Specific Targeted Therapeutics. <i>Clinical Cancer Research</i> , 2007, 13, 671s-679s.	3.2	131
222	Lung Cysts, Spontaneous Pneumothorax, and Genetic Associations in 89 Families with Birt-Hogg-DubÃ© Syndrome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 175, 1044-1053.	2.5	318
223	Genotype-Phenotype Correlation in von Hippel-Lindau Disease With Retinal Angiomatosis. <i>JAMA Ophthalmology</i> , 2007, 125, 239.	2.6	70
224	Targeting VEGF receptors in kidney cancer. <i>Lancet Oncology</i> , The, 2007, 8, 956-957.	5.1	14
225	Hereditary Leiomyomatosis and Renal Cell Cancer: A Syndrome Associated With an Aggressive Form of Inherited Renal Cancer. <i>Journal of Urology</i> , 2007, 177, 2074-2080.	0.2	235
226	Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine tumors (PNETs). <i>Surgery</i> , 2007, 142, 814-818.e2.	1.0	232
227	Protein expression profiling in the spectrum of renal tumors. <i>FASEB Journal</i> , 2007, 21, A181.	0.2	0
228	Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 15552-15557.	3.3	427
229	Multiple painful cutaneous nodules and renal mass. <i>Journal of the American Academy of Dermatology</i> , 2006, 55, 683-686.	0.6	22
230	Identification of the genes for kidney cancer. <i>Cancer Biology and Therapy</i> , 2006, 5, 696-699.	1.5	0
231	High Frequency of SDHB Germline Mutations in Patients with Malignant Catecholamine-Producing Paragangliomas: Implications for Genetic Testing. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 4505-4509.	1.8	299
232	Development of a Cell-Based Reporter Assay for Screening of Inhibitors of Hypoxia-Inducible Factor 2-Induced Gene Expression. <i>Journal of Biomolecular Screening</i> , 2006, 11, 678-687.	2.6	25
233	The genetic basis of cancer of kidney cancer: implications for gene-specific clinical management. <i>BJU International</i> , 2005, 95, 2-7.	1.3	43
234	HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: Novel role of fumarate in regulation of HIF stability. <i>Cancer Cell</i> , 2005, 8, 143-153.	7.7	843

#	ARTICLE	IF	CITATIONS
235	High Frequency of Somatic Frameshift BHD Gene Mutations in Birt-Hogg-DubÃ©-Associated Renal Tumors. <i>Journal of the National Cancer Institute</i> , 2005, 97, 931-935.	3.0	213
236	Management of von HippelÃ©-Lindau-associated kidney cancer. <i>Nature Reviews Urology</i> , 2005, 2, 248-255.	1.4	48
237	Germline BHD-Mutation Spectrum and Phenotype Analysis of a Large Cohort of Families with Birt-Hogg-DubÃ© Syndrome. <i>American Journal of Human Genetics</i> , 2005, 76, 1023-1033.	2.6	363
238	Partial adrenalectomy: The National Cancer Institute experience. <i>Urology</i> , 2005, 66, 19-23.	0.5	89
239	EVALUATION AND MANAGEMENT OF RENAL TUMORS IN THE BIRT-HOGG-DUBÃ© SYNDROME. <i>Journal of Urology</i> , 2005, 173, 1482-1486.	0.2	260
240	Expression of BirtÃ©-HoggÃ©-DubÃ© gene mRNA in normal and neoplastic human tissues. <i>Modern Pathology</i> , 2004, 17, 998-1011.	2.9	124
241	Focus on kidney cancer. <i>Cancer Cell</i> , 2004, 6, 223-228.	7.7	119
242	Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location. <i>Human Mutation</i> , 2004, 23, 40-46.	1.1	85
243	THE RELATIONSHIP BETWEEN RENAL TUMOR SIZE AND METASTASES IN PATIENTS WITH VON HIPPEL-LINDAU DISEASE. <i>Journal of Urology</i> , 2004, 172, 63-65.	0.2	181
244	PARENCHYMAL SPARING SURGERY FOR CENTRAL RENAL TUMORS IN PATIENTS WITH HEREDITARY RENAL CANCERS. <i>Journal of Urology</i> , 2004, 172, 49-53.	0.2	18
245	EARLY ONSET HEREDITARY PAPILLARY RENAL CARCINOMA: GERMLINE MISSENSE MUTATIONS IN THE TYROSINE KINASE DOMAIN OF THE MET PROTO-ONCOGENE. <i>Journal of Urology</i> , 2004, 172, 1256-1261.	0.2	115
246	Endolymphatic sac tumors in von HippelÃ©-Lindau disease. <i>Journal of Neurosurgery</i> , 2004, 100, 480-487.	0.9	83
247	Genetic Basis of Cancer of the Kidney. <i>Clinical Cancer Research</i> , 2004, 10, 6282S-6289S.	3.2	187
248	Diagnostic Localization of Malignant Bladder Pheochromocytoma Using 6-[18 F]Fluorodopamine Positron Emission Tomography. <i>Journal of Urology</i> , 2003, 169, 274-275.	0.2	24
249	A Phase I Study of Intravesical Suramin for the Treatment of Superficial Transitional Cell Carcinoma of the Bladder. <i>Journal of Urology</i> , 2003, 169, 357-360.	0.2	20
250	The Genetic Basis of Cancer of the Kidney. <i>Journal of Urology</i> , 2003, 170, 2163-2172.	0.2	447
251	von Hippel-Lindau disease. <i>Lancet, The</i> , 2003, 361, 2059-2067.	6.3	1,322
252	Mutations in the Fumarate Hydratase Gene Cause Hereditary Leiomyomatosis and Renal Cell Cancer in Families in North America. <i>American Journal of Human Genetics</i> , 2003, 73, 95-106.	2.6	563

#	ARTICLE	IF	CITATIONS
253	Studying Cancer Families to Identify Kidney Cancer Genes. Annual Review of Medicine, 2003, 54, 217-233.	5.0	66
254	Hereditary Renal Cancers. Radiology, 2003, 226, 33-46.	3.6	210
255	Biochemical Diagnosis of Pheochromocytoma. JAMA - Journal of the American Medical Association, 2002, 287, 1427-34.	3.8	994
256	Renal Tumors in the Birt-Hogg-Dub� Syndrome. American Journal of Surgical Pathology, 2002, 26, 1542-1552.	2.1	544
257	The contribution of VHL substrate binding and HIF1-� to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell, 2002, 1, 247-255.	7.7	421
258	Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dub� syndrome. Cancer Cell, 2002, 2, 157-164.	7.7	833
259	Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence. Cancer, 2002, 94, 690-699.	2.0	53
260	Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt-Hogg-Dub� syndrome. Cancer Epidemiology Biomarkers and Prevention, 2002, 11, 393-400.	1.1	177
261	PARENCHYMAL SPARING SURGERY IN A PATIENT WITH MULTIPLE BILATERAL PAPILLARY RENAL CANCER. Journal of Urology, 2001, 165, 1623-1624.	0.2	8
262	Birt-Hogg-Dub� Syndrome, a Genodermatosis Associated with Spontaneous Pneumothorax and Kidney Neoplasia, Maps to Chromosome 17p11.2. American Journal of Human Genetics, 2001, 69, 876-882.	2.6	355
263	PARENCHYMAL SPARING SURGERY IN PATIENTS WITH HEREDITARY RENAL CELL CARCINOMA: 10-YEAR EXPERIENCE. Journal of Urology, 2001, 165, 777-781.	0.2	198
264	LACK OF RETROPERITONEAL LYMPHADENOPATHY PREDICTS SURVIVAL OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA. Journal of Urology, 2001, 166, 68-72.	0.2	159
265	EXPRESSION STUDIES AND MUTATIONAL ANALYSIS OF THE ANDROGEN REGULATED HOMEBOX GENE NKX3.1 IN BENIGN AND MALIGNANT PROSTATE EPITHELIUM. Journal of Urology, 2001, 165, 1329-1334.	0.2	79
266	Recent Advances in Genetics, Diagnosis, Localization, and Treatment of Pheochromocytoma. Annals of Internal Medicine, 2001, 134, 315.	2.0	512
267	Partial adrenalectomy in patients with multiple adrenal tumors. Current Urology Reports, 2001, 2, 19-23.	1.0	12
268	Detection of loss of heterozygosity at chromosome 3p25-26 in primary and metastatic ovarian clear-cell carcinoma: Utilization of microdissection and polymerase chain reaction in archival tissues. Diagnostic Cytopathology, 2001, 24, 328-332.	0.5	18
269	Pheochromocytomas in von Hippel-Lindau Syndrome and Multiple Endocrine Neoplasia Type 2 Display Distinct Biochemical and Clinical Phenotypes. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1999-2008.	1.8	262
270	Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip. Drug Development Research, 2000, 49, 34-42.	1.4	144

#	ARTICLE	IF	CITATIONS
271	Development of a prostate cDNA microarray and statistical gene expression analysis package. , 2000, 28, 12-22.		80
272	Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis, 2000, 21, 2235-2242.	1.3	246
273	PREVALENCE OF MICROSCOPIC TUMORS IN NORMAL APPEARING RENAL PARENCHYMA OF PATIENTS WITH HEREDITARY PAPILLARY RENAL CANCER. Journal of Urology, 2000, 163, 431-433.	0.2	91
274	Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip. , 2000, 49, 34.		2
275	Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. , 2000, 21, 2235.		2
276	Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis, 2000, 21, 2235-2242.	1.3	7
277	Decreased expression of the pro-apoptotic protein Par-4 in renal cell carcinoma. Oncogene, 1999, 18, 1205-1208.	2.6	108
278	Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene, 1999, 18, 2343-2350.	2.6	487
279	Utilization of microdissection and the polymerase chain reaction for the diagnosis of adrenal cortical carcinoma in fine-needle aspiration cytology. , 1999, 87, 231-237.		12
280	INTERLEUKIN-2 BASED IMMUNOTHERAPY FOR METASTATIC RENAL CELL CARCINOMA WITH THE KIDNEY IN PLACE. Journal of Urology, 1999, 162, 43-45.	0.2	102
281	CLINICAL AND GENETIC CHARACTERIZATION OF PHEOCHROMOCYTOMA IN VON HIPPEL-LINDAU FAMILIES: COMPARISON WITH SPORADIC PHEOCHROMOCYTOMA GIVES INSIGHT INTO NATURAL HISTORY OF PHEOCHROMOCYTOMA. Journal of Urology, 1999, 162, 659-664.	0.2	233
282	RENAL CANCER IN FAMILIES WITH HEREDITARY RENAL CANCER: PROSPECTIVE ANALYSIS OF A TUMOR SIZE THRESHOLD FOR RENAL PARENCHYMAL SPARING SURGERY. Journal of Urology, 1999, 161, 1475-1479.	0.2	229
283	MANAGEMENT OF HEREDITARY PHEOCHROMOCYTOMA IN VON HIPPEL-LINDAU KINDREDS WITH PARTIAL ADRENALECTOMY. Journal of Urology, 1999, 161, 395-398.	0.2	97
284	Hereditary and Sporadic Papillary Renal Carcinomas with c-met Mutations Share a Distinct Morphological Phenotype. American Journal of Pathology, 1999, 155, 517-526.	1.9	243
285	Trisomy 7-harboring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nature Genetics, 1998, 20, 66-69.	9.4	291
286	Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Human Mutation, 1998, 12, 417-423.	1.1	452
287	Allelic Loss on Chromosome 8p in BRCA-1 Mutation Positive Breast/Ovarian Cancers. Breast Journal, 1998, 4, 9-12.	0.4	4
288	PSEUDOTUMORS AFTER RENAL PARENCHYMAL SPARING SURGERY. Journal of Urology, 1998, 159, 1148-1151.	0.2	14

#	ARTICLE	IF	CITATIONS
289	Multiple Neuroendocrine Tumors of the Pancreas in von Hippel-Lindau Disease Patients. American Journal of Pathology, 1998, 153, 223-231.	1.9	243
290	FAMILIAL RENAL ONCOCYTOMA: CLINICOPATHOLOGICAL STUDY OF 5 FAMILIES. Journal of Urology, 1998, 160, 335-340.	0.2	127
291	Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Human Mutation, 1998, 12, 417-423.	1.1	38
292	PULMONARY INFARCTS CAN MIMIC PULMONARY METASTASES FROM RENAL CANCER. Journal of Urology, 1997, 158, 1688-1690.	0.2	11
293	CYTOREDUCTIVE SURGERY BEFORE HIGH DOSE INTERLEUKIN-2 BASED THERAPY IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA. Journal of Urology, 1997, 158, 1675-1678.	0.2	120
294	Epididymal cystadenomas in von Hippel-Lindau disease. Urology, 1997, 49, 926-931.	0.5	96
295	Progelatinase A mRNA Expression in cell lines derived from tumors in patients with metastatic renal cell carcinoma correlates inversely with survival. Urology, 1997, 50, 295-301.	0.5	23
296	Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene, 1997, 15, 2233-2239.	2.6	298
297	Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nature Genetics, 1997, 16, 68-73.	9.4	1,461
298	Fine-needle aspiration of metastatic clear cell carcinoma of the kidney. Cancer, 1997, 81, 180-186.	2.0	21
299	Imaging Features of Hereditary Papillary Renal Cancers. Journal of Computer Assisted Tomography, 1997, 21, 737-741.	0.5	63
300	Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Human Mutation, 1996, 8, 348-357.	1.1	436
301	Isolated perfusion of the kidney with tumor necrosis factor for localized renal-cell carcinoma. World Journal of Urology, 1996, 14, S2-7.	1.2	10
302	Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Human Mutation, 1996, 8, 348-357.	1.1	33
303	Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: Correlations with phenotype. Human Mutation, 1995, 5, 66-75.	1.1	526
304	Loss of heterozygosity on the short arm of chromosome 3 in sporadic, von hippel-lindau disease-associated, and familial pheochromocytoma. Genes Chromosomes and Cancer, 1995, 13, 151-156.	1.5	48
305	Original Articles: Kidney Cancer: Parenchymal Sparing Surgery in Patients With Hereditary Renal Cell Carcinoma. Journal of Urology, 1995, 153, 913-916.	0.2	87
306	Original Articles: Kidney Cancer: Hereditary Papillary Renal Cell Carcinoma: Clinical Studies in 10 Families. Journal of Urology, 1995, 153, 907-912.	0.2	176

#	ARTICLE	IF	CITATIONS
307	Characterization of the Renal Pathology of a Familial Form of Renal Cell Carcinoma Associated With Von Hippel-Lindau Disease: Clinical and Molecular Genetic Implications. <i>Journal of Urology</i> , 1995, 153, 22-26.	0.2	143
308	Prevalence of Microscopic lesions in Grossly Normal Renal Parenchyma from Patients with von Hippel-Lindau Disease, Sporadic Renal Cell Carcinoma and No Renal Disease: Clinical Implications. <i>Journal of Urology</i> , 1995, 154, 2010-2015.	0.2	170
309	Loss of heterozygosity on the short arm of chromosome 3 in mesothelioma cell lines and solid tumors. <i>Genes Chromosomes and Cancer</i> , 1994, 11, 15-20.	1.5	32
310	Hereditary Papillary Renal Cell Carcinoma. <i>Journal of Urology</i> , 1994, 151, 561-566.	0.2	289
311	Evaluation of Color Doppler Intraoperative Ultrasound in Parenchymal Sparing Renal Surgery. <i>Journal of Urology</i> , 1994, 152, 1984-1987.	0.2	44
312	Flow cytometric DNA analysis of interleukin-2 responsive renal cell carcinoma. <i>Journal of Surgical Oncology</i> , 1993, 53, 252-255.	0.8	4
313	Identification of the von Hippel-Lindau disease tumor suppressor gene. <i>Science</i> , 1993, 260, 1317-1320.	6.0	2,723
314	Regression of Metastatic Renal Cell Carcinoma After Cytoreductive Nephrectomy. <i>Journal of Urology</i> , 1993, 150, 463-466.	0.2	132
315	Molecular Genetics of Tumor Suppressor Genes in Prostate Carcinoma: the Challenge and the Promise Ahead. <i>Journal of Urology</i> , 1992, 147, 808-809.	0.2	10
316	A pilot trial of chemohormonal therapy for metastatic prostate carcinoma. <i>Cancer</i> , 1992, 69, 213-218.	2.0	18
317	A Report of Familial Carotid Body Tumors and Multiple Extra-Adrenal Pheochromocytomas. <i>Journal of Urology</i> , 1991, 145, 1040-1042.	0.2	31
318	Surgical Management of Pheochromocytoma with the Use of Metyrosine. <i>Annals of Surgery</i> , 1990, 212, 621-628.	2.1	101
319	Preparative Cytoreductive Surgery in Patients with Metastatic Renal Cell Carcinoma Treated with Adoptive Immunotherapy with Interleukin-2 or Interleukin-2 Plus Lymphokine Activated Killer Cells. <i>Journal of Urology</i> , 1990, 144, 614-617.	0.2	90
320	Renal Cell Carcinoma. <i>Journal of Urology</i> , 1988, 139, 340-341.	0.2	4
321	The effect of 4MA, a potent inhibitor of 5 alpha-reductase, on the growth of androgen-responsive human genitourinary tumors grown in athymic nude mice. <i>Prostate</i> , 1987, 10, 189-197.	1.2	21
322	Aids Case for Diagnosis, 1986 <i>Military Medicine</i> . <i>Military Medicine</i> , 1986, 151, M49-M56.	0.4	0
323	Serial analysis of gene expression in renal carcinoma cells reveals VHL-dependent sensitivity to TNF α cytotoxicity. , 0, .		1